Low-Dose Naltrexone for Depression and Mental Health: An Emerging Option

By Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho

Naltrexone is an FDA-approved medication most people associate with addiction treatment — it blocks opioid receptors and is used to reduce cravings in opioid and alcohol use disorders. But at a fraction of the standard dose, naltrexone does something entirely different. It modulates the immune system, reduces neuroinflammation, and may have meaningful benefits for depression, anxiety, chronic pain, and autoimmune conditions.

This is the world of low-dose naltrexone (LDN) — one of the more intriguing developments in integrative and functional medicine over the past two decades.

Standard naltrexone doses for addiction treatment range from 50–100mg per day. Low-dose naltrexone uses doses typically between 1.5mg and 4.5mg — roughly 1/10th to 1/20th of the standard dose.

At these low doses, naltrexone's mechanism of action shifts dramatically. Rather than continuously blocking opioid receptors, LDN produces a brief, transient blockade (typically taken at bedtime) that triggers a rebound upregulation of the body's endogenous opioid system. This rebound effect is thought to be responsible for many of LDN's therapeutic benefits.

But the more clinically significant mechanism may be LDN's effects on glial cells — specifically microglia, the brain's resident immune cells.

Over the past decade, neuroinflammation has emerged as a major factor in depression, anxiety, and other psychiatric conditions. Elevated levels of inflammatory cytokines (IL-6, TNF-alpha, IL-1beta) are consistently found in patients with major depression, and anti-inflammatory interventions have shown antidepressant effects in clinical trials.

Microglia are the primary drivers of neuroinflammation. When activated — by stress, infection, trauma, or metabolic dysfunction — they release pro-inflammatory cytokines that disrupt neurotransmitter synthesis, impair neuroplasticity, and contribute to the symptoms of depression.

LDN appears to work in part by modulating microglial activity. Specifically, it acts as an antagonist at Toll-like receptor 4 (TLR4) — a receptor on microglia that, when activated, triggers inflammatory cascades. By blocking TLR4, LDN reduces microglial activation and the downstream neuroinflammation that contributes to depression and other conditions.

This mechanism is distinct from all conventional antidepressants, which work primarily on monoamine neurotransmitters (serotonin, norepinephrine, dopamine). LDN addresses a different pathway entirely — which is why it may help patients who haven't responded to standard treatments.

The evidence for LDN in depression is preliminary but promising. A 2019 pilot study found that LDN produced significant reductions in depressive symptoms in patients with treatment-resistant depression, with a response rate of approximately 50%. A 2023 randomized controlled trial found that LDN augmentation (added to existing antidepressant therapy) produced greater symptom reduction than placebo augmentation.

Several case series and observational studies have reported antidepressant effects of LDN, particularly in patients with elevated inflammatory markers or comorbid autoimmune conditions.

The evidence for LDN in anxiety is less developed than for depression, but several studies have noted anxiolytic effects as a secondary finding. The proposed mechanism — reduction of neuroinflammation and modulation of the endogenous opioid system — is plausible for anxiety as well, given the role of both systems in fear and stress responses.

LDN has the strongest evidence base in chronic pain conditions, particularly fibromyalgia. A 2013 randomized controlled trial found that LDN significantly reduced fibromyalgia pain compared to placebo, with a good safety profile. Multiple subsequent studies have replicated these findings.

This is clinically relevant for mental health because chronic pain and depression are deeply intertwined — each worsens the other, and they share overlapping neurobiological mechanisms. Treating the pain component with LDN may have downstream benefits for mood.

LDN has been studied in multiple sclerosis, Crohn's disease, and other autoimmune conditions, with promising results in some trials. The immune-modulating mechanism makes it theoretically applicable to any condition driven by dysregulated inflammation.

LDN may be worth considering for patients who:

• Have treatment-resistant depression that hasn't responded to multiple antidepressants
• Have elevated inflammatory markers (high CRP, elevated cytokines)
• Have comorbid autoimmune conditions (Hashimoto's, lupus, MS, IBD)
• Have comorbid fibromyalgia or chronic pain
• Are interested in a low-side-effect augmentation strategy
• Prefer a non-stimulant, non-controlled substance option

It is generally not the first treatment tried for depression — conventional options should be explored first. But for patients with an inflammatory or autoimmune component to their illness, LDN represents a mechanistically distinct and potentially valuable option.

LDN has a favorable safety profile. The most common side effects are:

• Vivid dreams or sleep disturbances — most common when starting, often resolves within 1–2 weeks; taking the dose in the morning rather than at bedtime can help
• Mild nausea — usually transient
• Fatigue — uncommon, typically resolves

LDN does not cause dependence, withdrawal, or cognitive impairment. It is not a controlled substance.

Important contraindications:

• LDN cannot be used by patients taking opioid medications (it will precipitate withdrawal)
• It should be used cautiously in patients with liver disease
• It requires a prescription and should be obtained from a compounding pharmacy (standard naltrexone tablets are 50mg and cannot simply be split)

At Roth Family Medicine and Mental Health, we take an integrative approach to treatment-resistant depression and mental health. For patients with an inflammatory component to their illness — evidenced by elevated inflammatory markers, comorbid autoimmune conditions, or a history of poor response to conventional antidepressants — LDN is one of several tools we consider.

Our evaluation process includes:

• Comprehensive lab work including inflammatory markers (CRP, ESR, cytokines)
• Thyroid and metabolic assessment
• Review of prior treatment history
• Discussion of all available options, including LDN, ketamine therapy, TMS, and others

LDN is not a magic bullet, and it's not right for everyone. But for the right patient, it can be a meaningful piece of a comprehensive treatment plan.

If you're struggling with depression that hasn't responded to standard treatments, we'd welcome the opportunity to explore whether LDN or other integrative approaches might be appropriate for you.

Kyle Roth, FNP-BC, APRN, MSN, MHA is a board-certified family nurse practitioner at Roth Family Medicine and Mental Health in Pocatello, Idaho, specializing in treatment-resistant depression, ketamine therapy, TMS, hormone optimization, and integrative mental health care. To schedule a consultation, visit ZocDoc or call (208) 904-4705.